BioInvent International AB (publ) (STO:BINV)
Sweden
· Delayed Price · Currency is SEK 23.60
+0.25 (1.07%)
Feb 21, 2025, 5:29 PM CET
STO:BINV Revenue
BioInvent International AB had revenue of 12.76M SEK in the quarter ending September 30, 2024, a decrease of -52.37%. This brings the company's revenue in the last twelve months to 38.64M, down -49.68% year-over-year. In the year 2023, BioInvent International AB had annual revenue of 71.46M, down -78.09%.
Revenue (ttm)
38.64M
Revenue Growth
-49.68%
P/S Ratio
40.22
Revenue / Employee
335.97K
Employees
111
Market Cap
1.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
| Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
| Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
| Dec 31, 2020 | 147.37M | 53.63M | 57.21% |
| Dec 31, 2019 | 93.74M | 55.19M | 143.18% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.03B |
| Getinge AB | 34.76B |
| Sectra AB | 3.14B |
| Camurus AB | 1.87B |
| Medicover AB | 23.97B |
| Vitrolife AB | 3.61B |
| Elekta AB | 17.72B |
| Vimian Group AB | 4.29B |
BioInvent International AB News
- 5 months ago - Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments - Benzinga